

# Robert BodÃ©n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3448252/publications.pdf>

Version: 2024-02-01

64  
papers

1,470  
citations

393982

19  
h-index

344852

36  
g-index

68  
all docs

68  
docs citations

68  
times ranked

2497  
citing authors

#	ARTICLE	IF	CITATIONS
1	A blinded validation of the Swedish version of the Clinical Assessment Interview for Negative Symptoms (CAINS). <i>Nordic Journal of Psychiatry</i> , 2022, 76, 44-51.	0.7	4
2	Modulation of dorsolateral prefrontal cortex functional connectivity after intermittent theta-burst stimulation in depression: Combining findings from fNIRS and fMRI. <i>NeuroImage: Clinical</i> , 2022, 34, 103028.	1.4	11
3	Application of positron emission tomography in psychiatry—methodological developments and future directions. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	8
4	Modulation of the prefrontal blood oxygenation response to intermittent theta-burst stimulation in depression: A sham-controlled study with functional near-infrared spectroscopy. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 247-256.	1.3	8
5	Lithium influences whole-organism metabolic rate in <i>Drosophila subobscura</i> . <i>Journal of Neuroscience Research</i> , 2021, 99, 407-418.	1.3	0
6	Ambulatory Heart Rate Variability in Schizophrenia or Depression. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 121-128.	0.7	6
7	Unchanged Cognitive Performance and Concurrent Prefrontal Blood Oxygenation After Accelerated Intermittent Theta-Burst Stimulation in Depression: A Sham-Controlled Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 659571.	1.3	2
8	Dorsomedial prefrontal theta burst stimulation to treat anhedonia, avolition, and blunted affect in schizophrenia or depression—a randomized controlled trial. <i>Journal of Affective Disorders</i> , 2021, 290, 308-315.	2.0	23
9	Inhibitory and excitatory neurotransmitter systems in depressed and healthy: A positron emission tomography and magnetic resonance spectroscopy study. <i>Psychiatry Research - Neuroimaging</i> , 2021, 315, 111327.	0.9	14
10	Response rate and subjective memory after electroconvulsive therapy in depressive disorders with psychiatric comorbidity. <i>Journal of Affective Disorders</i> , 2021, 292, 276-283.	2.0	10
11	Suppressing visual hallucinations in an adolescent by occipital transcranial magnetic stimulation: A single-case experimental research design. <i>Neuropsychological Rehabilitation</i> , 2021, , 1-10.	1.0	0
12	Habitual caffeine consumption moderates the antidepressant effect of dorsomedial intermittent theta-burst transcranial magnetic stimulation. <i>Journal of Psychopharmacology</i> , 2021, 35, 1536-1541.	2.0	4
13	Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 451-459.	1.8	10
14	Exposure to risperidone versus other antipsychotics and risk of osteoporosis-related fractures: a population-based study. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 74-83.	2.2	7
15	Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study. <i>Addiction</i> , 2020, 115, 768-777.	1.7	20
16	Predictors of Treatment Response to Electroconvulsive Therapy in Schizophrenia—A Nationwide Registry-Based Study. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	5
17	Intermittent theta burst stimulation over the dorsomedial prefrontal cortex modulates resting-state connectivity in depressive patients: A sham-controlled study. <i>Behavioural Brain Research</i> , 2020, 394, 112834.	1.2	17
18	A register-based approach to identifying treatment-resistant depression—Comparison with clinical definitions. <i>PLoS ONE</i> , 2020, 15, e0236434.	1.1	15

#	ARTICLE	IF	CITATIONS
19	Transcranial magnetic intermittent theta-burst stimulation for depression in pregnancy â€“ A case series. <i>Brain Stimulation</i> , 2020, 13, 1665-1667.	0.7	5
20	Pain trajectories of dorsomedial prefrontal intermittent theta burst stimulation versus sham treatment in depression. <i>BMC Neurology</i> , 2020, 20, 311.	0.8	1
21	Coffee Consumption Moderates the Antidepressant Effect of Transcranial Magnetic Stimulation. <i>Biological Psychiatry</i> , 2020, 87, S261-S262.	0.7	1
22	Risk of Delayed Discharge and Reoperation of Gastric Bypass Patients with Psychiatric Comorbidityâ€”a Nationwide Cohort Study. <i>Obesity Surgery</i> , 2020, 30, 2511-2518.	1.1	12
23	Autonomic modulation networks in schizophrenia: The relationship between heart rate variability and functional and structural connectivity in the brain. <i>Psychiatry Research - Neuroimaging</i> , 2020, 300, 111079.	0.9	4
24	Suicide Ideation and Behavior as Risk Factors for Subsequent Suicide in Schizophrenia: A Nested Caseâ€“Control Study. <i>Suicide and Life-Threatening Behavior</i> , 2019, 49, 996-1005.	0.9	12
25	All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population. <i>Annals of General Psychiatry</i> , 2019, 18, 23.	1.2	44
26	A case of bipolar disorder onset with subsequent catatonia in a 14-year-old boy treated successfully with electroconvulsive therapy. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 497-500.	0.7	1
27	Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort study. <i>European Neuropsychopharmacology</i> , 2019, 29, 691-700.	0.3	16
28	Treatmentâ€“resistant depression as risk factor for substance use disordersâ€”a nationâ€“wide registerâ€“based cohort study. <i>Addiction</i> , 2019, 114, 1274-1282.	1.7	21
29	Initiation and longâ€“term use of benzodiazepines and Zâ€“drugs in bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 634-646.	1.1	22
30	Persistent tachycardia in clozapine treated patients: A 24-hour ambulatory electrocardiogram study. <i>Schizophrenia Research</i> , 2018, 199, 403-406.	1.1	12
31	Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study. <i>BMC Psychiatry</i> , 2018, 18, 352.	1.1	34
32	Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden. <i>Journal of Affective Disorders</i> , 2018, 238, 674-679.	2.0	64
33	955. Striatal Phosphodiesterase 10A and Medial Prefrontal Cortical Thickness in Patients with Schizophrenia: A PET and MRI Study. <i>Biological Psychiatry</i> , 2017, 81, S386-S387.	0.7	0
34	Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations. <i>Journal of Affective Disorders</i> , 2017, 217, 16-23.	2.0	15
35	Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study. <i>Translational Psychiatry</i> , 2017, 7, e1050-e1050.	2.4	24
36	Suicide, Self-harm, and Depression After Gastric Bypass Surgery. <i>Annals of Surgery</i> , 2017, 265, 235-243.	2.1	68

#	ARTICLE	IF	CITATIONS
37	Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections. <i>International Clinical Psychopharmacology</i> , 2017, 32, 219-224.	0.9	18
38	Risk factors for suicide among patients with schizophrenia: a cohort study focused on cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 1711-1714.	1.0	11
39	Postinjection Delirium Syndrome Associated With Olanzapine Long-Acting Injectable. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 388-389.	0.7	3
40	Suicide risk and antipsychotic side effects in schizophrenia: nested case-control study. <i>Human Psychopharmacology</i> , 2016, 31, 341-345.	0.7	14
41	Re: Pregabalin prescriptions in the United Kingdom - a drug utilisation study of The Health Improvement Network (THIN) primary care database by Asomaning et al.. <i>International Journal of Clinical Practice</i> , 2016, 70, 696-696.	0.8	1
42	Higher mortality after myocardial infarction in patients with severe mental illness: a nationwide cohort study. <i>Journal of Internal Medicine</i> , 2015, 277, 727-736.	2.7	52
43	Diabetes and glucose disturbances in patients with psychosis in Sweden. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000120.	1.2	6
44	Predictors for initiation of pharmacological prophylaxis in patients with newly diagnosed bipolar disorder - A nationwide cohort study. <i>Journal of Affective Disorders</i> , 2015, 172, 204-210.	2.0	10
45	Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. <i>International Journal of Clinical Practice</i> , 2014, 68, 104-110.	0.8	43
46	Psychomotor and cognitive deficits as predictors of 5-year outcome in first-episode schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 282-288.	0.7	10
47	Factors associated with pregabalin dispensing at higher than the approved maximum dose. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 197-204.	0.8	46
48	Neuropeptide Y, social function and long-term outcome in schizophrenia. <i>Schizophrenia Research</i> , 2014, 156, 223-227.	1.1	17
49	Suicide in first episode psychosis: A nationwide cohort study. <i>Schizophrenia Research</i> , 2014, 157, 1-7.	1.1	47
50	A five year diagnostic follow-up of 1840 patients after a first episode non-schizophrenia and non-affective psychosis. <i>Schizophrenia Research</i> , 2013, 150, 205-210.	1.1	15
51	Medication and suicide risk in schizophrenia: A nested case-control study. <i>Schizophrenia Research</i> , 2013, 150, 416-420.	1.1	37
52	Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 987-995.	1.0	69
53	Antipsychotic Prescription Filling in Patients With Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 759-765.	0.7	8
54	A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 371.	1.0	20

#	ARTICLE	IF	CITATIONS
55	Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. <i>BMJ, The</i> , 2012, 345, e7085-e7085.	3.0	185
56	Antipsychotics During Pregnancy. <i>Archives of General Psychiatry</i> , 2012, 69, 715-21.	13.8	111
57	Antidopaminergic drugs and acute pancreatitis: a population-based study. <i>BMJ Open</i> , 2012, 2, e000914.	0.8	7
58	Electrocardiographic signs of autonomic imbalance in medicated patients with first-episode schizophrenia spectrum disorders â€“ relations to first treatment discontinuation and five-year remission status. <i>European Psychiatry</i> , 2012, 27, 213-218.	0.1	3
59	FC19-02 - Electrocardiographic signs of autonomic imbalance in first-episode schizophrenia spectrum disordersâ€” relations to first treatment discontinuation and five-year remission status. <i>European Psychiatry</i> , 2011, 26, 1916-1916.	0.1	1
60	FC19-01 Antipsychotic and antidepressive pharmacotherapy in relation to suicide risk in schizophrenia. <i>European Psychiatry</i> , 2011, 26, 1915-1915.	0.1	0
61	Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , 2011, 133, 36-41.	1.1	72
62	Five-year outcome of first-episode psychosis before and after the implementation of a modified assertive community treatment programme. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2010, 45, 665-674.	1.6	21
63	Association between symptomatic remission and functional outcome in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2009, 107, 232-237.	1.1	110
64	Biochemical risk factors for development of obesity in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2009, 115, 141-145.	1.1	13